Back to UBS Group AG UBS Group AG

PBYIPBYI
Showing 8 of 30 quarters

Position history for UBS Group AGUBS Group AG's holdings in PUMA BIOTECHNOLOGY INC

UBS Group AG holds 636,761 shares of PBYI (PUMA BIOTECHNOLOGY INC), worth $5.2M as of 2026-Q2. The position was increased (+19.2% shares). PBYI represents 0.0% of UBS Group AG's portfolio.

Current Value

$5.2M

Current Shares

636,761

Total Value Change

+$5.1M

Total Shares Change

+609,667

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
636,761
+19.2%
$5.2M0.0%$8.11
32
2026-Q1
Increased
534,227
+319.6%
$3.4M0.0%$6.21
43
2025-Q4
Decreased
127,312
-66.2%
$757,5060.0%$6.01
0
2025-Q3
Increased
376,091
+37.2%
$2M0.0%$5.05
34
2025-Q2
Decreased
274,100
-2.0%
$940,1630.0%$3.33
0
2025-Q1
Increased
279,667
+79.8%
$827,8140.0%$3.14
38
2024-Q4
Increased
155,571
+474.2%
$474,4920.0%$3.13
39
2024-Q3
Increased
27,094
+33.3%
$69,0900.0%$2.58
18

Other major holders of PBYI: BLACKROCK ADVISORS LLC, FEDERATED HERMES, INC., BNP PARIBAS FINANCIAL MARKETS, FRED ALGER MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used